Lupus Patients at Risk for Heart Failure
Patients with SLE are at increased risk for HF, not just of MI and stroke, with risk similar to that of patients with diabetes, researchers found in an analysis of Medicaid data.
News
RheumNow Podcast – Late Breaking Abstract Wrap-Up (6.21.19)
Dr. Jack Cush reviews the week’s news and wrap up from EULAR19.
EULAR 2019 - Podcast #1
This EULAR 2019 Podcast is a compilation of audio clips from EULAR 2019 in Madrid.
No Difference Among Biologics in Arthroplasty Infectious Risk
A large administrative claims analysis of rheumatoid arthritis (RA) patients undergoing arthroplasty has shown no difference among biologics with regard to the risk of infections, but corticosteroid use was associated with a dose dependent risk of infection.
Allopurinol Fails to Curtail Hypertension
A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.
Hypertension is one of the many comorbidities that plagues gout patients.
ACP Guidelines on Developing Evidence Based Clinical Guidelines
Recommendations for the screening, diagnosis, and treatment of various diseases often differ by organization, making it difficult to know which ones to follow.
Borrelia burgdorferi Peptidoglycan Shedding Drives Lyme Arthritis
Research published in PNAS has shown that long after active Lyme infection in the joint, a peptidoglycan (PG) of the the spirochete Borrelia burgdorferi can be found in the joints of those with late-stage Lyme disease.
Is Methotrexate Necessary with Tofacitinib?
Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.
EULAR 2019- Day 4 Report
Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster.
Below are the top “LB” presentations from EULAR this year:
Understanding Non-arthritic Rheumatic iRAEs
A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.
Blinded by the Use of Antimalarials in Lupus?
Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD.
Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis
Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.
